Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK.

Breast Cancer Res Treat. 2018 Jun 25. doi: 10.1007/s10549-018-4852-5. [Epub ahead of print]

PMID:
29938395
2.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 May 9. doi: 10.1007/s10549-018-4813-z. [Epub ahead of print]

PMID:
29744674
3.

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.

Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP.

Breast Cancer Res Treat. 2018 May 7. doi: 10.1007/s10549-018-4807-x. [Epub ahead of print] Review.

PMID:
29736741
4.

Financial Impact of Breast Cancer in Black Versus White Women.

Wheeler SB, Spencer JC, Pinheiro LC, Carey LA, Olshan AF, Reeder-Hayes KE.

J Clin Oncol. 2018 Jun 10;36(17):1695-1701. doi: 10.1200/JCO.2017.77.6310. Epub 2018 Apr 18.

5.

PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.

Puvanesarajah S, Nyante SJ, Kuzmiak CM, Chen M, Tse CK, Sun X, Allott EH, Kirk EL, Carey LA, Perou CM, Olshan AF, Henderson LM, Troester MA.

Cancer Prev Res (Phila). 2018 Jun;11(6):327-336. doi: 10.1158/1940-6207.CAPR-17-0368. Epub 2018 Apr 5.

6.

Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Apr 4;556(7699):135. doi: 10.1038/nature26162.

PMID:
29620732
7.

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM.

J Clin Invest. 2018 Apr 2;128(4):1371-1383. doi: 10.1172/JCI96153. Epub 2018 Feb 26.

8.

Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Feb 15;554(7692):378-381. doi: 10.1038/nature25465. Epub 2018 Feb 7. Erratum in: Nature. 2018 Apr 4;556(7699):135.

PMID:
29414946
9.

Influence of provider factors and race on uptake of breast cancer gene expression profiling.

Reeder-Hayes KE, Wheeler SB, Baggett CD, Zhou X, Meng K, Roberts MC, Carey LA, Meyer AM.

Cancer. 2018 Apr 15;124(8):1743-1751. doi: 10.1002/cncr.31222. Epub 2018 Jan 16.

PMID:
29338090
10.

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC.

Clin Breast Cancer. 2017 Oct 28. pii: S1526-8209(17)30313-0. doi: 10.1016/j.clbc.2017.10.014. [Epub ahead of print]

PMID:
29153866
11.

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.

Nyrop KA, Deal AM, Choi SK, Wagoner CW, Lee JT, Wood A, Anders C, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Muss HB.

Breast Cancer Res Treat. 2018 Feb;168(1):43-55. doi: 10.1007/s10549-017-4565-1. Epub 2017 Nov 9.

PMID:
29124455
12.

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

Nyrop KA, Deal AM, Lee JT, Muss HB, Choi SK, Wheless A, Carey LA, Shachar SS.

Breast Cancer Res Treat. 2018 Jan;167(1):235-248. doi: 10.1007/s10549-017-4501-4. Epub 2017 Sep 14.

PMID:
28913660
13.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

PMID:
28877533
14.

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.

Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG, Anders CK.

Clin Breast Cancer. 2018 Feb;18(1):29-37. doi: 10.1016/j.clbc.2017.07.017. Epub 2017 Aug 9.

15.

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx135.

PMID:
28859290
16.

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS.

J Clin Invest. 2017 Sep 1;127(9):3472-3483. doi: 10.1172/JCI90499. Epub 2017 Aug 21.

17.

Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.

Reeder-Hayes KE, Meyer AM, Hinton SP, Meng K, Carey LA, Dusetzina SB.

J Clin Oncol. 2017 Oct 10;35(29):3298-3305. doi: 10.1200/JCO.2016.71.4345. Epub 2017 Jul 20.

PMID:
28727517
18.

De-escalating and escalating systemic therapy in triple negative breast cancer.

Carey LA.

Breast. 2017 Aug;34 Suppl 1:S112-S115. doi: 10.1016/j.breast.2017.06.041. Epub 2017 Jul 8.

PMID:
28690105
19.

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.

Breast Cancer Res Treat. 2017 Aug;165(1):181-191. doi: 10.1007/s10549-017-4303-8. Epub 2017 Jun 2.

PMID:
28577078
20.

Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Partridge AH, Carey LA.

Clin Cancer Res. 2017 Jun 1;23(11):2611-2616. doi: 10.1158/1078-0432.CCR-16-2633.

21.

Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.

Nyrop KA, Deal AM, Lee JT, Muss HB, Choi SK, Dixon S, Wheless A, Carey LA, Shachar SS.

Breast Cancer Res Treat. 2017 Apr;162(2):375-388. doi: 10.1007/s10549-017-4106-y. Epub 2017 Feb 2.

PMID:
28155053
22.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

23.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.

24.

Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.

Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER.

PLoS Med. 2017 Jan 9;14(1):e1002222. doi: 10.1371/journal.pmed.1002222. eCollection 2017 Jan.

25.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.

Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA.

NPJ Precis Oncol. 2017;1. pii: 24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25.

26.

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.

27.

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.

Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER.

PLoS Med. 2016 Dec 6;13(12):e1002174. doi: 10.1371/journal.pmed.1002174. eCollection 2016 Dec. Erratum in: PLoS Med. 2017 Jan 9;14 (1):e1002222.

28.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

29.

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.

30.

Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.

Mohiuddin JJ, Deal AM, Carey LA, Lund JL, Baker BR, Zagar TM, Jones EL, Marks LB, Chen RC.

J Am Coll Surg. 2016 Nov;223(5):717-728.e4. doi: 10.1016/j.jamcollsurg.2016.08.541.

PMID:
27788894
31.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.

32.

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study.

Chollet-Hinton L, Anders CK, Tse CK, Bell MB, Yang YC, Carey LA, Olshan AF, Troester MA.

Breast Cancer Res. 2016 Aug 4;18(1):79. doi: 10.1186/s13058-016-0736-y.

33.

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).

Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH.

Breast Cancer Res Treat. 2016 Aug;159(1):109-18. doi: 10.1007/s10549-016-3918-5. Epub 2016 Jul 22.

34.

I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.

Carey LA, Winer EP.

N Engl J Med. 2016 Jul 7;375(1):83-4. doi: 10.1056/NEJMe1603691. No abstract available.

PMID:
27406352
35.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

36.

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA.

J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2.

37.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA.

JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.

PMID:
27078022
38.

Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.

Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB.

J Clin Oncol. 2016 Jun 10;34(17):2003-9. doi: 10.1200/JCO.2015.65.8716. Epub 2016 Apr 11.

39.

Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer.

Gatza ML, Carey LA.

J Clin Oncol. 2016 Jun 1;34(16):1838-9. doi: 10.1200/JCO.2015.66.3872. Epub 2016 Mar 28. No abstract available.

PMID:
27022119
40.

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT.

NPJ Breast Cancer. 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6.

41.

Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi.

Gutnik LA, Matanje-Mwagomba B, Msosa V, Mzumara S, Khondowe B, Moses A, Kohler RE, Carey LA, Lee CN, Gopal S.

J Glob Oncol. 2015 Dec 23;2(1):4-8. doi: 10.1200/JGO.2015.000430. eCollection 2016 Feb. No abstract available.

42.

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

McKee MJ, Keith K, Deal AM, Garrett AL, Wheless AA, Green RL, Benbow JM, Dees EC, Carey LA, Ewend MG, Anders CK, Zagar TM.

Oncologist. 2016 Jan;21(1):16-20. doi: 10.1634/theoncologist.2015-0328. Epub 2015 Dec 9.

43.

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.

Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB.

J Clin Oncol. 2016 Jan 10;34(2):130-8. doi: 10.1200/JCO.2015.63.2489. Epub 2015 Nov 23.

44.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

45.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

46.

CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.

Carey LA.

Clin Cancer Res. 2015 Sep 15;21(18):4027-9. doi: 10.1158/1078-0432.CCR-14-3124.

47.

Neoadjuvant clinical trial designs: Challenges of the genomic era.

Carey LA.

Breast. 2015 Nov;24 Suppl 2:S88-90. doi: 10.1016/j.breast.2015.07.021. Epub 2015 Aug 1.

PMID:
26243441
48.

Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.

Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB.

Breast Cancer Res Treat. 2015 Aug;153(1):191-200. doi: 10.1007/s10549-015-3518-9. Epub 2015 Jul 28.

49.

Palbociclib--Taking Breast-Cancer Cells Out of Gear.

Carey LA, Perou CM.

N Engl J Med. 2015 Jul 16;373(3):273-4. doi: 10.1056/NEJMe1506680. No abstract available.

PMID:
26176385
50.

Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.

Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM.

Breast Cancer Res Treat. 2015 Jul;152(2):347-56. doi: 10.1007/s10549-015-3476-2. Epub 2015 Jun 25.

Supplemental Content

Loading ...
Support Center